3-Chloro-4-fluorobenzonitrile | CAS:117482-84-5

We serve 3-Chloro-4-fluorobenzonitrile CAS:117482-84-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Chloro-4-fluorobenzonitrile

Chemical Name:3-Chloro-4-fluorobenzonitrile
CAS.NO:117482-84-5
Synonyms:3-Chloro-4-fluorobenzonitrile
3-chloro-4-fluoro benzonitrile
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 213.6±20.0 °C at 760 mmHg
Melting Point 69-71 °C(lit.)
Molecular Formula C7H3ClFN
Molecular Weight 155.557
Flash Point 83.0±21.8 °C
Vapour Pressure 0.2±0.4 mmHg at 25°C
Index of Refraction 1.537
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 3-Chloro-4-fluorobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-chloro-4-fluoro benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-chloro-4-fluoro benzonitrile Use and application,3-chloro-4-fluoro benzonitrile technical grade,usp/ep/jp grade.


Related News: We are pleased to work with Inceptua, given their strong record of administering such programs successfully.”phenyl isothiocyanate manufacturer Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.(2-bromo-4-fluorophenyl)methanol supplier Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality.BOC-PHE-OBZL vendor The Philippines reported its first Wuhan coronavirus fatality on Sunday.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.